Precision medicine in diabetic macular edema

The application of precision medicine in diabetic macular edema has been one of the main topics of Symposium “Inflammatory Approach in DME: Building Precision Medicine”, Promoted by Allergan, a subsidiary of AbbVie. It must be remembered that this took place in the framework of the 25th Congress of the Spanish Society of Retina and Vitreous (SERV).

As experts have pointed out, the individualization of the treatment that the patient will receive is approaching. All this thanks to the presence of biomarkers that allow us to predict a good response to an inflammatory approach to this disease.

More information was provided by Giacomo Panozzo, specialist in retinal diseases and professor at the European School for Advanced Studies in Ophthalmology (ESASO), in Switzerland. In fact, he himself is the first author of the article published in the European Journal of Ophthalmology on ESASO classification. This classification is intended to provide ophthalmologists with a simple, direct and objective tool for classifying diabetic macular edema. The same, Together with the use of imaging biomarkers, it allows precision medicine to be implemented in diabetic macular edema.

“The classification we provide, based on the characteristics of biomarkers obtained by OCT, allows for individualization of a treatment that has not yet existed,” said Panuzzo.

Precision medicine in diabetic macular edema

The goal of DME treatments is to prevent deterioration of the macula. To do this, the edema is reduced before it becomes chronic and the damage is irreversible. To make decisions about the optimal treatment, specialists already have a key tool: biomarkers. This has shown its predictive value on response to treatment. In this way, treatment can be individualized by taking into account the predominant pathophysiological mechanism in each patient. Namely, for advances in precision medicine in diabetic macular edema.

The use of biomarkers plays a fundamental role in allowing ESASO classification. bliss The rating is valid for both naïve eyes and those who have already been treated. In addition, regardless of the nature of the treatment that was followed by the patient.

The most relevant aspect of this classification is that It allows to standardize the situation in which patients find themselves. In this way it helps in making treatment decisions for them. Vitality arrived. Panozzo, this rating “is another tool for improving accuracy in the DME approach. It allows professionals to make appropriate treatment decisions for each patient’s DME condition and progression, based on scientific evidence.”

Leave a Reply

Your email address will not be published.